8 Apr in 13:00
Just one day will be enough to update Russia s EpiVacCorona vaccine to ensure protection against new mutations of the coronavirus, the Russian State Research Center of Virology and Biotechnology Vector s General Director Rinat Maksyutov said. If the virus suddenly mutates, and a mutation occurs in the areas where we selected peptides, if we need to update the vaccine, then it will take no more than one day to upgrade vaccine composition, Maksyutov said.
Vector s director clarified that developing peptides and releasing a vaccine takes time, apart from that, research must be conducted for the updated vaccine. I hope that it will be possible to conduct just an abbreviated study, like we do with seasonal influenza vaccines when new strains appear, but, since there have been no precedents with a coronavirus vaccine so far, it is difficult to say anything for sure, everything will depend on the regulator, Sputnik cited Maksyutov as saying.
Vaccines against COVID-19 can be altered to fight new strains, developer says
It s not necessary to conduct pre-clinical and clinical trials, General Director of the Vector State Research Center of Virology and Biotechnology Rinat Maksyutov said
MOSCOW, April 1. /TASS/. Vaccines against the coronavirus can be quickly altered in the future if new strains emerge, without conducting pre-clinical and clinical trials, General Director of the Vector State Research Center of Virology and Biotechnology Rinat Maksyutov said in an interview with RT on Wednesday. Annually, on the basis of data on circulating strains of the flu virus the formulation of vaccines is being determined and altered if necessary. For example, for the Northern hemisphere, at the end of February the WHO determines the formulation of vaccines for the next epidemic season and beginning in March, using updated strains of the flu virus, the production of a vaccine begins in order to launch mass inoculation in the fall,
Despite the pandemic-related challenges, Russia progresses with vaccination at home and abroad pressenza.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pressenza.com Daily Mail and Mail on Sunday newspapers.
PM Mishustin visits Russia s only WHO avian influenza reference laboratory
KOLTSOVO, Novosibirsk region. March 5 (Interfax) - Russian Prime Minister Mikhail Mishustin has visited the Vector State Research Center of Virology and Biotechnology.
Head of Russian health watchdog Rospotrebnadzor Anna Popova and Vector General Director Rinat Maksyutov gave the prime minister and his delegation a tour of the Vector Center s department of zoonotic infections and influenza.
First, Mishustin was shown the protective suits worn by laboratory employees in the Red Zone. The prime minister asked whether the production of such suits is a problem. Maksyutov said that the main problem is making a heavy-duty reusable suit that can be disinfected using formalin vapors.
MOSCOW, March 5. /TASS/. Mass inoculation with the EpiVacCorona vaccine developed by Russia’s State Research Center of Virology and Biotechnology Vector will begin in the second half of March, the center’s Director General Rinat Maksyutov told Vesti news show on Rossiya 1 Friday. Our fellow citizens will be able to get vaccinated [with EpiVacCorona] starting in the second half of March, he said.
In October 2020, EpiVacCorona became the second coronavirus vaccine registered in Russia. The vaccine consists of artificially synthesized short fragments of viral proteins - peptides - that make the immune system recognize and neutralize the virus.